secwatch / observer
8-K filed December 7, 2023, 6:59 PM ET ticker CPRX CIK 0001369568
leadership confidence high sentiment positive materiality 0.75

Catalyst Pharma appoints Michael Kalb as CFO; Alicia Grande to retire at year-end 2023

CATALYST PHARMACEUTICALS, INC.

item 5.02item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael W. Kalb

Executive Vice President and Chief Financial Officer
CPRX · CATALYST PHARMACEUTICALS, INC.
Effective
2024-01-01
Filed
December 7, 2023, 6:59 PM ET
On December 4, 2023, the Company announced the appointment of Michael W. Kalb as the Company's Executive Vice President and CFO, effective January 1, 2024.
Role change

Jeffrey Del Carmen

Executive Vice President, Chief Commercial Officer
CPRX · CATALYST PHARMACEUTICALS, INC.
Effective
2024-01-01
Filed
December 7, 2023, 6:59 PM ET
and of Jeffrey Del Carmen to Executive Vice President, Chief Commercial Officer
Departed

Alicia Grande

Chief Financial Officer
CPRX · CATALYST PHARMACEUTICALS, INC.
Effective
2023-12-31
Successor
Michael W. Kalb
Filed
December 7, 2023, 6:59 PM ET
On December 1, 2023, Alicia Grande, the Chief Financial Officer ("CFO") of Catalyst Pharmaceuticals, Inc. (the " Company ") informed the Company of her intent to retire as the Company's CFO at the end of 2023.
Role change

Steven Miller

Executive Vice President, Chief Operating and Scientific Officer
CPRX · CATALYST PHARMACEUTICALS, INC.
Effective
2024-01-01
Filed
December 7, 2023, 6:59 PM ET
the Company reported the promotion, effective on January 1, 2024, of Dr. Steven Miller to Executive Vice President, Chief Operating and Scientific Officer

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael W. Kalb was appointed as Executive Vice President and Chief Financial Officer at CATALYST PHARMACEUTICALS, INC..

Action
appointed
Role
Executive Vice President and Chief Financial Officer
Exact text from the filing
On December 4, 2023, the Company announced the appointment of Michael W. Kalb as the Company's Executive Vice President and CFO, effective January 1, 2024.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Jeffrey Del Carmen changed role as Executive Vice President, Chief Commercial Officer at CATALYST PHARMACEUTICALS, INC..

Action
promoted
Role
Executive Vice President, Chief Commercial Officer
Exact text from the filing
and of Jeffrey Del Carmen to Executive Vice President, Chief Commercial Officer
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Alicia Grande retired as Chief Financial Officer at CATALYST PHARMACEUTICALS, INC..

Action
retired
Role
Chief Financial Officer
Exact text from the filing
On December 1, 2023, Alicia Grande, the Chief Financial Officer ("CFO") of Catalyst Pharmaceuticals, Inc. (the " Company ") informed the Company of her intent to retire as the Company's CFO at the end of 2023.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Steven Miller changed role as Executive Vice President, Chief Operating and Scientific Officer at CATALYST PHARMACEUTICALS, INC..

Action
promoted
Role
Executive Vice President, Chief Operating and Scientific Officer
Exact text from the filing
the Company reported the promotion, effective on January 1, 2024, of Dr. Steven Miller to Executive Vice President, Chief Operating and Scientific Officer
View on SEC.gov

CATALYST PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR
accession 0001193125-23-290725
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.